U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449156) titled 'A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.' on Feb. 27.
Brief Summary: The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.
Study Start Date: March 27
Study Type: INTERVENTIONAL
Condition:
Acne Vulgaris
Intervention:
DRUG: HB0043
300mg
DRUG: Placebo
300mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....